Clinical Trial Update: A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 study evaluating Tabelecleucel for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder in patients after rituximab failure; the t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-transplant Lymphoproliferative Disorder

Drugs mentioned

• Tabelecleucel (tabelecleucel)

Snippet

Sponsor: Pierre Fabre Medicament | Conditions: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications | Phase 3 | Status: RECRUITING